Antitumor Activity
DISEASE
No patients in cohorts Q2W-LD or Q3W experienced a confirmed partial or complete response. In cohort Q2W-LD overall, 10 patients had stable disease (time to progression range: 1.5–7.2 months; 5 patients ≥4 months), 15 patients had progressive disease, and 3 patients were not evaluable (no post-baseline evaluation). Six of 13 patients who received a LD of 170 mg/m² had stable disease. In cohort Q3W overall, 6 patients had stable disease (time to progression range: 1.2–2.8 months), 7 patients had progressive disease, and 2 patients were not evaluable. Two of 6 patients who received 170 mg/m² Q3W had stable disease.